Huron, Degenerative Brain Disease Quantitative Analysis AI Solution Published in SCIE Journal

Brain PET Image Quantitative Analysis AI Solution
Heuron Brain PET Accuracy Proven
Paper Published in Scientific Reports

Medical artificial intelligence (AI) solution company Heuron announced on the 28th that its positron emission tomography (PET) quantitative analysis AI solution for diagnosing degenerative brain diseases, 'Heuron Brain PET,' has been published in the SCIE-level international journal Scientific Reports. Brain PET scans are one of the nuclear medicine examination methods. Brain PET images are mainly interpreted visually, but the interpretation results can vary depending on the examiner's expertise, and there can be cases where visual interpretation is ambiguous.

Heuron Brain PET is a solution that utilizes AI to fuse PET, which shows functional changes in the brain, and magnetic resonance imaging (MRI), which represents the brain's anatomical state. It subdivides the brain into 105 regions and automatically quantifies and provides the standardized uptake value ratio (SUVR) and volume values for PET tracers in each region. This study was conducted in collaboration with Heuron and Professor Youngsil Ahn from the Department of Nuclear Medicine at Ajou University Hospital. Using data from 408 patients who underwent brain PET, the quantitative values of the widely used nuclear medicine quantification product PMOD and Heuron Brain PET were compared.

The study results showed no statistically significant difference in performance between the two products in evaluating amyloid deposition in brain PET. Heuron Brain PET demonstrated excellent diagnostic performance with a sensitivity of 96.69% and specificity of 95.55% in diagnosing the presence or absence of amyloid deposition. While PMOD's analysis time was about 10 minutes, Heuron Brain PET analyzed in 3 to 5 minutes, more than twice as fast. These results indicate that Heuron Brain PET provides quantified PET values more conveniently, minimizing differences in results due to the interpreter's level of expertise.

Shin Donghoon, CEO of Heuron, said, “We are pleased to be able to demonstrate the technological capability of Heuron Brain PET through this paper,” and added, “Heuron Brain PET can be used for early diagnosis of degenerative brain diseases, clinical research, and new drug development, and demand is expected to continue to increase in the future.”

This content was produced with the assistance of AI translation services.